Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)

Figures & data

Figure 1 Mechanism of action of imatinib (source: http:\\wikipedia/imatnib [accessed March 2, 2009]).

Figure 2 Intraoperative photograph of advanced GIST after imatinib therapy showing multiple tumor nodules on the bowel and mesentery despite a good radiographic response. Resection of this disease requires an aggressive approach, which frequently includes peritonectomy/omentectomy, multivisceral resections, and resection of liver (courtesy Dr C Corless).

Table 1 Outcomes of resection in patients with advanced GIST on tyrosine kinase inhibitors (n = 69)

	Stable disease	Limited progression	Generalized progression
R0–R1	78%	25%	7%
R2	4%	16%	43%
1-year PFS	80%	33%	0%
1-year OS	95%	86%	0%

Adapted with permission from Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumorsafter treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31.³² Copyright © 2006 American Society of Clinical Oncology.

Abbreviations: R0–R1, complete resection of all microscopic or macroscopic disease, respectively; R2, gross residual disease left behind; PFS, progression-free survival; OS, overall survival.

RautCPPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol2006242325233116710031

 PubMed Web of Science ®Google Scholar